Sangamo Looks Forward After Shire Returns Hemophilia Rights
This article was originally published in Scrip
Executive Summary
Sangamo Biosciences touted the progress of its in vivo protein replacement platform (IVPRP) as it reported that Shire relinquished its rights to hemophilia programs under the companies' three-year-old collaboration, but investors were wary about the loss of an important alliance for two out or four partnered programs as well as the exchange of milestone fees for total control of preclinical assets.
You may also be interested in...
Gilead Partners With Sangamo For Gene Editing As It Builds Up Kite's Cell Therapy Platform
Gilead committed more than $3bn via its subsidiary Kite to license Sangamo's zinc finger technology for gene editing that may deliver improved T cell therapies for cancer. More deals are expected in this space as Gilead builds its cell therapy platform after buying Kite last year.
Biogen Shores Up Gene Therapy Ambitions With New Deal
Biogen Inc. has furthered its gene therapy ambitions by entering into a broad alliance with the University of Pennsylvania that could see it paying out up to $2bn in research funding and other payments. Biogen has made a series of moves over the past couple of years to build up its gene therapy research.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.